U.S. FDA approves antibody to protect infants from RSV

FDA approves antibody to protect infants from RSV | CNN Parents and pediatricians will have a new option this fall to protect babies from a lung-attacking virus that is the leading cause of hospitalization in infants under a year of age in the United States every year. Brenda Goodman CNN

...

Nirsevimab, which will be sold under the brand name Beyfortus, is not a vaccine. Vaccines prompt the body to make antibodies to defend against pathogens. Instead, nirsevimab is a form of passive immunity. It’s a ready-made antibody that can bind to the virus and block it from infecting healthy cells. The immune system doesn’t have to make anything.

...